Effects of combination therapy: @entity1943 analogues and XXXX agonists on @entity2338 and @entity442 levels in @entity2012 .

@entity1 @entity2338 @entity2847 @entity9229 @entity935 @entity442 @entity2012 @entity977 @entity18245 @entity2390 @entity1943 @entity652 @entity4903
BACKGROUND AND AIMS: @entity2012 is a @entity4903 caused by excessive secretion of @entity2338 , secondary to a @entity2338 secreting @entity977 or a mixed @entity977 secreting @entity2338 and PRL. METHODS: The aim of this study was to evaluate the effects of combination therapy: @entity935 agonist and @entity1943 analogue on @entity2338 and @entity442 levels in a group of 30 @entity1 with @entity2012 . @entity9229 in a dose of 2 mg/week and 4 mg/week respectively was associated with @entity2390 LAR in a dose of 20 mg/month and 30 mg/months respectively. Eight @entity1 were treated with @entity18245 30 mg/week and @entity9229 2 mg/week and 3 @entity1 were treated with @entity2847 10 mg/day and @entity2390 LAR 30 mg/month. RESULTS: Combination therapy: @entity9229 and @entity2390 achieved normal levels of @entity442 in 32% of the @entity1 , better results being obtained after 12 months of treatment in the group treated with 4 mg @entity9229 /week. In 37% of cases the levels of @entity442 decreased by 50% after 12 months of treatment. In the group treated with @entity9229 and Somatuline a normal level of @entity442 was achieved in 25% of @entity1 after 12 months of treatment. The outcome for the group treated with @entity2390 and @entity2847 was similar to that obtained under @entity9229 2 mg/week. There was no significant correlation between the level of @entity2338 and the type or dose of @entity935 agonist used. CONCLUSIONS: In conclusion, combination therapy consisting of @entity935 agonist and @entity1943 analogue achieves a significant reduction of @entity442 levels in @entity1 with mixed @entity652 secreting @entity2338 and PRL. A decrease in @entity442 levels is directly correlated with the dose of @entity9229 used.
